What Insurance Do Investors Require at Series A for a Life Sciences Company?

A Series A term sheet routinely carries insurance requirements a founder has never seen before. The three that surprise people most are directors and officers insurance, a step up in liability limits, and real diligence on the program itself. Founders who wait until closing to deal with these slow the round, because the coverage cannot always be placed on a signing-week timeline. This is the Series A point on the broader arc in how insurance changes at each funding stage.

Why Series A Changes the Insurance Conversation

At seed, insurance follows the company’s own activity. At Series A, it also has to satisfy the people writing the check. Institutional investors take board seats and bring fiduciary exposure with them, and they read the insurance program as part of protecting their investment and their directors. The conversation shifts from “what does the company need” to “what does the company need plus what do the investors require,” and the second half is often the part founders have not planned for.

The result is that the program becomes a gating item for the close. A round can be ready on every other front and still wait on a policy that should have been placed weeks earlier.

The Three Common Surprises

The first is directors and officers insurance. The institutional director placed by the lead will typically require D&O before accepting the seat, because it is the mechanism that protects directors and officers personally when the company cannot indemnify them. For a device company this is the same reason a device company adds D&O once it has a board or investors. The detailed Series A view of how investors weigh the program is in digital health insurance for a Series A raise.

The second is limits. The liability lines a company carried at seed are often sized below what a Series A investor expects, and the term sheet or the diligence checklist will call for higher limits across general liability, product or professional liability, and cyber. The third is diligence itself: investor counsel examines the actual policies, not just a summary, and reads them against the company’s regulatory profile, surfacing gaps the founder did not know were there.

Some rounds also raise representations and warranties or specific contractual insurance terms, but for most life sciences companies the D&O requirement, the limit step-up, and the diligence review are the three that drive the work.

Time the Placement to the Round, Not the Close

The avoidable failure is treating insurance as a closing checklist item. D&O placement takes underwriting time, raising limits takes time, and curing a gap that diligence surfaces takes time. A program rebuilt during the signing week can push the close, which is the opposite of what a founder wants at that moment. The companies that handle it well start the insurance work when the term sheet arrives, so the program is ready when counsel asks.

Two practical moves help. First, get a representative copy of the investor’s insurance requirements early, while diligence is open, so the gaps are known with time to fix them. Second, keep the company’s documentation current, because both diligence and underwriting run on it, and a clean record speeds both. Building well at seed, as covered in the seed-stage piece of this series, makes the Series A review far easier.

What to Do Now

When a Series A term sheet is in hand, treat insurance as a workstream of the raise, not an afterthought of the close. Confirm whether D&O is required and place it early, check your current limits against what the investor expects, and have your broker pre-empt the diligence by reviewing the program against your regulatory profile. The aim is for insurance to be the easy part of the close rather than the item that delays it.

Before your next round closes, confirm the program already meets the investor’s requirements rather than scrambling to meet them in signing week. A specialty review through Tower Street Insurance can align a life sciences company’s coverage to what Series A investors actually require, on a timeline that does not hold up the round.